Tafinlar 75 mg hard capsules
Sponsors
Oslo University Hospital HF, Akershus University Hospital, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Institut National De La Sante Et De La Recherche Medicale, HUS-Yhtymae
Conditions
Acute myeloid leukemiaAdvanced CancerAdvanced solid tumorCancerChronic myelomonocyte leukemiaMetastatic non-clear cell renal cell carcinomaMultiple myelomaMyelodysplastic syndrome
Phase 2
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Start: 2016-07-25Target: 3000Updated: 2025-12-19
Improving public cancer care by implementing precision medicine in Norway
A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway
RecruitingCTIS2023-507894-16-00
Start: 2021-04-01Target: 6000Updated: 2026-01-22
Precision therapy versus standard therapy in Acute Myeloid Leukaemia and Myelodysplastic syndrome in elderly (PALM) – a phase II randomized clinical trial
CompletedCTIS2023-509092-16-00
End: 2025-11-27Target: 33Updated: 2024-10-18
A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma
Active, not recruitingCTIS2024-519070-39-00
Start: 2020-03-06Target: 30Updated: 2024-10-31
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile
Not yet recruitingCTIS2024-517478-68-01
Target: 250Updated: 2024-11-06
Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE.
RecruitingCTIS2024-513779-42-02
Start: 2025-03-27Target: 100Updated: 2025-10-10